Liquidia Corporation (NASDAQ: LQDA) has announced a presentation on YUTREPIA studies by Dr Samdeep Sahay. The drug, which is still under investigation, is a treprostinil dry powder, which patients take through a practical device.
The company used its PRINT technology to develop YUTREPIA
The U.S Food and Drug Administration gave tentative approval to the therapy to treat pulmonary arterial hypertension. This therapy enhances exercise capability in patients.
The company designed YUTREPIA via its PRINT technology.
The PRINT technology platform allowed the company to develop drug particles with similar composition, shape, and size. Liquidia also designed the therapy to ensure optimal lung deposition.
Liquidia has ready conducted a Phase III clinical trial to test the pharmacology and efficacy of the drug in patients with pulmonary arterial hypertension who are treprostinil naive and who are weaning off Tyvaso.
Liquidia, a biotechnology company, develops drugs through PRINT technology to treat various indications. The company also focuses on developing and marketing drugs made from this platform to treat pulmonary hypertension. YUTREPIA is one of its lead drugs.
Since the PRINT technology platform enables Liquidia to create precise chemical compositions for its drug, it creates additional benefits for patients. For example, the company could limit the side effects of therapy, improve stability and storage, develop novel combinations, find the best routes for administration, increase drug loading, and prolong the release of a drug.
The company used the technology to develop treprostinil
Another medication that the company creates using its technology is the treprostinil injection. The company works with Sandoz through its subsidiary to develop a generic form of this drug. Liquidia develops the drug to treat pulmonary arterial hypertension.
The side effects of treprostinil are hypotension, joint pain, muscle pain, dizziness, headaches, diarrhoea, skin reddening, and jaw pain, among others. While the drug has no contraindications, patients should still be careful about its usage. For example, they shouldn’t quit their medication without consulting a doctor.
Physicians should also be careful when administering treprostinil to patients with kidney or liver problems, as it could be harmful.
The company also works through its two subsidiaries, that is, Liquidia PAH, LLC and Liquidia Technologies, Inc. The company which has its headquarters in Morrisville, North Carolina, mainly operates in the U.S.